Gilead Sciences Inc (GILD) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Total Assets Chart for Gilead Sciences Inc

Gilead Sciences Inc (GILD) total assets for FY2025 were USD 59.0B, a 0.0% change from FY2024. Gilead Sciences Inc's total assets grew from USD 12.5M in 1990 to USD 59.0B in 2025 (472084.0% over 35 years). Total assets compound annual growth rate: 5-year CAGR of -2.9%, 10-year CAGR of 1.3%, 20-year CAGR of 14.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$162.47B
Implied Share Price
$130.86
Enterprise Value
$182.45B
Revenue (TTM)
$30.46B
EBITDA
$15.24B
Profit Margin
-10.64%
Trailing P/E
—
Forward P/E
15.22
Price/Book (MRQ)
14.30
Price/Sales (TTM)
5.33
EV/EBITDA
12.25
EV/Revenue
5.99
Dividend Yield
2.44%
Book Value
$9.46
Free Cash Flow (FY2025)
$9.46B
Free Cash Flow Yield
5.82%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.